← FDA DRUG APPROVALS

FDA NDA · NDA212271

CONTEPO

fosfomycin disodium

Sponsor: MEITHEAL

APPLICATION
NDA212271
TYPE
NDA
ORIGINAL APPROVAL
2025-10-22
LATEST ACTION
2025-10-22
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

CONTEPO · ReferencePrescription
FOSFOMYCIN DISODIUM EQ 6GM BASE/VIAL · POWDER · INTRAVENOUS

Approval history

2025-10-22Type 2 - New Active Ingredient · Original · priorityLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →